P-352 Docetaxel, oxaliplatin, and 5-fluorouracil in metastatic gastric/gastroesophageal junction adenocarcinoma: A single-center experience

Abstract

The combination of docetaxel, cisplatin, and 5-fluorouracil (5-FU) demonstrated high response rates in advanced gastric cancer, albeit with increased toxicity. Given the efficacy of platinum-taxane-fluoropyrimidine regimens, in this retrospective study we evaluated the efficacy and toxicity of docetaxel, oxaliplatin, and 5-FU (DOF) for the treatment of metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma. In this study, 34 patients with metastatic gastric or GEJ adenocarcinoma who were treated with DOF regimen between January 2017 and June 2019 were retrospectively evaluated. Chemotherapy was administered every 14 days, with combined docetaxel (50 mg/m2) and oxaliplatin (85 mg/m2) followed by 5FU (2400 mg/m2). Overall Response Rate (ORR) and Disease Control Rate (DCR) were 58.8% and 70.6%, respectively. Median Progression Free Survival (PFS) and Overall Survival (OS) were 9.4 months (95% CI [6.4-11.3]) and 14.6 months (95% CI [11.8-21.6]), respectively. Grade 3-4 toxicities occurred in 21 patients (61.7%), including neutropenia (20.3%), neurologic (18.9%), and diarrhea (16.0%). DOF demonstrated a high response rate, expected safety profile, and prolonged survival and remains an option for select patients with metastatic gastric or GEJ adenocarcinoma.